Working to Eradicate Gynecologic Cancers

MPPR
Featured Posters I: Meet the Professor Reception: Connecting Minds for a Better Future

Saturday, March 28, 2015: 5:30 PM-6:30 PM
Salon C-D (Hilton Chicago)
Description: Featured posters represent the highest ranked among all poster submissions. Participate in the new featured posters session that follows a "Meet the Professor" format. This 60-minute session will explore a variety of topics through peer-to-peer dialogue. There are limited spots available and all topic areas are first come, first seated. Topics will be provided prior to the session. There will be a wine and cheese reception within the Exhibit Hall.
5:30 PM
61
Predictive value of p16INK4a and Ki-67 immunohistochemical staining in expectant management of cervical intraepithelial neoplasia grade 2
E. Miralpeix, G. Mancebo, J. M. Sole-Sedeno, J. Genoves, B. Lloveras, J. Gimeno, F. Alameda, B. Bellosillo and R. Carreras
Hospital del Mar, Barcelona, Spain
 
5:30 PM
62
Complete responses in the irradiated field following treatment with chemotherapy with and without bevacizumab in advanced cervical cancer: an NRG Oncology/Gynecologic Oncology Group study
R. N. Eskander1, J. Java2, B. J. Monk3 and K. S. Tewari4
1University of California at Irvine Medical Center, Orange, CA, 2Gynecologic Oncology Group Statistical and Data Center, Buffalo, NY, 3University of Arizona Cancer Center, Phoenix, AZ, 4UC Irvine Medical Center, Orange, CA
 
5:30 PM
63
Evaluation of WHO-endorsed ‘see and treat' cervical cancer screening in HIV-positive and HIV-negative women in Cameroon
L. S. Bradford1, G. A. DeGregorio2, P. Tih3, R. Wamai4, Z. Sando5, E. Welty6, T. Welty3, L. Kennedy-Sheldon7 and J. G. Ogembo7
1University of Massachusetts, Worcester, MA, 2University of Massachusetts Medical School, Worcester, MA, 3Cameroon Baptist Convention Health Services, Bamenda, Northwest Province, Cameroon, 4Northeastern University, Boston, MA, 5University of Yaoundé, Yaoundé, Cameroon, 6Cameroon Baptist Convention Health Board, Bamenda, Northwest Province, Cameroon, 7University of Massachusetts Medical Center, Worcester, MA
 
5:30 PM
64
High versus low-dose rate brachytherapy for locally advanced cervical cancer
S. S. Patankar1, A. I. Tergas2, W. M. Burke2, J. Y. Hou2, C. Ananth1, Y. Huang1, A. Neugut1, D. Hershman1 and J. D. Wright2
1Columbia University College of Physicians and Surgeons, New York, NY, 2NYP/Columbia University Medical Center, New York, NY
 
5:30 PM
65
Abdominal radical trachelectomy: what can we learn from recurrent cases
J. Li and X. Wu
Fudan University Shanghai Cancer Center, Shanghai, China
 
5:30 PM
66
Cervical stenosis following abdominal radical trachelectomy: a report of 10-year experience
J. Li and X. Wu
Fudan University Shanghai Cancer Center, Shanghai, China
 
5:30 PM
67
Chemoradiation vs. neoadjuvant chemoradiation followed by radical surgery for FIGO stage III cervical cancer: analysis of complications and 3-year survival
F. Fanfani1, G. Monterossi1, E. Vizza2, F. Landoni3, P. De Iaco4, G. Corrado2, S. Colangione3, A. M. Perrone4, G. Scambia1 and A. Fagotti5
1Catholic University of the Sacred Heart, Milan, Italy, 2Istituto Nazionale Tumori Regina Elena, Rome, Italy, 3European Institute of Oncology, Milan, Italy, 4S.Orsola-Malpighi Hospital, Bologna, Italy, 5Catholic University of the Sacred Heart, Rome, Italy
 
5:30 PM
68
Is parametrectomy in early stage cervical cancer always necessary?
G. Baiocchi, L. Y. Kumagai, H. Mantoan, L. Badiglian-Filho, C. Faloppa, E. Fukazawa, L. De Brot and A. A. B. A. Costa
A.C. Camargo Cancer Center, São Paulo, Brazil
 
5:30 PM
69
Abdominal radical trachelectomy for early stage cervical cancer: fertility sparing approach
A. Rodolakis1, N. Thomakos1, I. Koutroumpa1, M. Sotiropoulou1, D. Haidopoulos1, G. Vlachos1 and D. Loutradis2
1Alexandra Hospital, University of Athens, Athens, Greece, 2University of Athens School of Medicine, Alexandra Hospital, Athens, Greece
 
5:30 PM
70
Biodistribution and therapeutic potential of 177Lu-labeled antibody targeting human papillomavirus E6 oncoprotein in a cervical cancer model
J. F. Gutierrez1, R. Phaeton2,3, Z. Jiang1, E. Dadachova1 and G. L. Goldberg2
1Albert Einstein College of Medicine, Bronx, NY, 2Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, 3Penn State College of Medicine, Hershey, PA
 
5:30 PM
71
Utility of HPV genotyping in the management of low-grade squamous intraepithelial cervical lesions (LSIL)
J. M. Sole-Sedeno, G. Mancebo, E. Miralpeix, B. Lloveras, B. Bellosillo, I. Aran, R. Alarcon, F. Alameda and R. Carreras
Hospital del Mar, Barcelona, Spain
 
5:30 PM
72
Association between statin use and disease specific endometrial cancer survival
A. R. Van Arsdale, M. H. Einstein, G. Kaur, H. Strickler, A. Moadel, E. Girda, G. L. Goldberg and N. S. Nevadunsky
Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY
 
5:30 PM
73
Chemotherapy toxicity and quality of life in older women with advanced or recurrent endometrial cancer: an NRG Oncology – Gynecologic Oncology Group ancillary study
E. M. Ko1, J. Java2, L. Van Le3, K. Schmitz4, M. E. Randall5, J. D. Bloss6, G. Fleming7, D. H. Moore8, B. J. Monk9 and H. B. Muss10
1University of Pennsylvania, Penn Medicine, Philadelphia, PA, 2Gynecologic Oncology Group Statistical and Data Center, Buffalo, NY, 3University of North Carolina at Chapel Hill, Chapel Hill, NC, 4Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 5University of Kentucky Medical Center, Lexington, KY, 6Astella Pharma, Northbrook, IL, 7University of Chicago Medical Center, Chicago, IL, 8Franciscan Physician Network Gynecologic Oncology Specialists, Indianapolis, IN, 9University of Arizona Cancer Center, Phoenix, AZ, 10University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC
 
5:30 PM
74
Recent trends in the utilization of lymphadenectomy among patients undergoing surgery for endometrioid adenocarcinoma of the endometrium: an analysis of the Surveillance, Epidemiology, and End Results database, 1998-2010
A. Melamed1, J. T. Clemmer2, J. A. Rauh-Hain2, R. M. Clark2, M. del Carmen2, A. Goodman2, W. B. Growdon2, J. O. Schorge2 and D. M. Boruta II2
1Brigham and Women's Hospital/Massachussets General Hospital, Boston, MA, 2Massachusetts General Hospital/Harvard University, Boston, MA
 
5:30 PM
75
An international comparison of surgically staged patients with serous and clear cell endometrial carcinoma
J. A. Ducie1, A. G. Z. Eriksson1, B. J. Mosgaard2, L. Nedergaard3, H. Lajer4, N. R. Abu-Rustum1, M. M. Leitao1 and C. Hogdall2
1Memorial Sloan Kettering Cancer Center, New York, NY, 2Juliane Marie Centre, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark, 3Rigshospitalet, University of Copenhagen, Copenhagen, Denmark, 4Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
 
5:30 PM
76
An international comparison of surgical staging approaches in patients with intermediate- and high-risk endometrioid endometrial cancer
J. A. Ducie1, A. G. Z. Eriksson1, L. Nedergaard2, H. Lajer3, B. J. Mosgaard4, N. R. Abu-Rustum1, C. Hogdall4 and M. M. Leitao1
1Memorial Sloan Kettering Cancer Center, New York, NY, 2Dagens Medicin, København, Denmark, 3Rigshospitalet, University of Copenhagen, Copenhagen, Denmark, 4Juliane Marie Centre, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
 
5:30 PM
77
Outcomes of patients with stage I endometrial cancer in the sentinel lymph node era
Y. Sonoda, A. G. Erikkson, J. A. Ducie, E. Jewell, G. J. Gardner, C. L. Brown, O. Zivanovic, D. A. Levine, D. S. Chi, N. R. Abu-Rustum and M. M. Leitao
Memorial Sloan Kettering Cancer Center, New York, NY
 
5:30 PM
78
Patterns of practice and outcomes of definitive radiation therapy in early stage inoperable endometrial cancer
B. S. Gill, K. J. Hansen, P. Sukumvanich and S. Beriwal
Magee-Womens Hospital of UPMC, Pittsburgh, PA
 
5:30 PM
79
Impact of surgical staging and adjuvant therapy on recurrence risk and outcome in stage I non-invasive uterine papillary serous carcinoma
H. Mahdi1, R. DeBernardo1, M. Elshaikh2, A. R. Munkarah2, D. Isrow2, S. Singh3, S. E. Waggoner3, R. Ali4, J. Harding5, R. T. Morris6 and M. Moslemi-Kebria1
1Cleveland Clinic, Cleveland, OH, 2Henry Ford Health System, Detroit, MI, 3University Hospitals Case Medical Center, Cleveland, OH, 4Wayne State University, Detroit, MI, 5Case Western Reserve Univesity, Cleveland, OH, 6Wayne State University School of Medicine, Detroit, MI
 
5:30 PM
80
Do stage I-II uterine clear cell carcinoma patients need to be treated as aggressively as patients with serous carcinoma?
T. J. Yang, N. Desai, M. Kollmeier, V. Makker, M. M. Leitao, N. R. Abu-Rustum and K. Alektiar
Memorial Sloan Kettering Cancer Center, New York, NY
 
5:30 PM
81
The impact of adjuvant therapy on survival in uterine clear cell carcinoma patients
A. A. Gockley1, J. A. Rauh-Hain2, J. T. Clemmer2, R. M. Clark2, T. R. Hall1, A. Goodman2, D. M. Boruta II2, M. del Carmen1, W. B. Growdon2 and J. O. Schorge2
1Massachusetts General Hospital, Boston, MA, 2Massachusetts General Hospital/Harvard University, Boston, MA
 
5:30 PM
82
Statin use significantly improves overall survival in high-grade endometrial cancer
C. H. Feng1, C. M. Miller2, M. M. Salgia3, M. E. Tenney3, N. K. Lee3, S. D. Yamada3 and Y. Hasan3
1University of Chicago, Pritzker School of Medicine, Chicago, IL, 2Drexel University College of Medicine, Philadelphia, PA, 3University of Chicago, Chicago, IL
 
5:30 PM
83
Is VTE prophylaxis overkill? A comparison of VTE incidence in robotic and laparoscopic surgery for endometrial cancer
A. H. Freeman1, A. Barrie1, L. Lyon2, C. Garcia1, L. H. Abbott1, R. D. Littell1 and B. Powell1
1Kaiser Permanente San Francisco Medical Center, San Francisco, CA, 2Kaiser Permanente Medical Group Division of Research, San Francisco, CA
 
5:30 PM
84
Universal screening for Lynch syndrome in endometrial cancer results in increased acceptance of genetic counseling and testing
A. Frolova1, S. Babb2, E. Zantow2, M. A. Powell1, P. H. Thaker1, A. R. Hagemann1 and D. G. Mutch1
1Washington University School of Medicine, St. Louis, MO, 2Washington University School of Medicine St. Louis, St Louis, MO
 
5:30 PM
85
Clinicopathologic factors predictive of concurrent endometrial carcinoma in women with a preoperative diagnosis of endometrial hyperplasia
A. A. Ramzan1, M. R. Gualtieri1, P. Mhawech-Fauceglia1, K. Graham1, M. Ciccone1, C. Dancz1, Y. Ueda2, L. D. Roman1 and K. Matsuo1
1LAC+USC Medical Center, Los Angeles, CA, 2Osaka University Graduate School of Medicine, Osaka, Japan
 
5:30 PM
86
Same day discharge after laparoscopic hysterectomy for endometrial cancer
A. Melamed1,2, J. L. Katz Eriksen1,2, E. M. Hinchcliff1,2, M. Worley3, R. S. Berkowitz1,2,4, N. S. Horowitz1,2,4, M. G. Muto1,2,5 and C. M. Feltmate1,2,5
1Harvard Medical School, Boston, MA, 2Brigham and Women's Hospital, Boston, MA, 3Robert Wood Johnson Medical School, New Brunswick, NJ, 4Dana-Farber Cancer Institute, Boston, MA, 5Dana Farber Cancer Institute, Boston, MA
 
5:30 PM
87
An international collaboration for comparison of two approaches to surgical staging of low-risk endometrial cancer
A. G. Z. Eriksson1, H. Lajer2, B. J. Mosgaard3, J. A. Ducie1, M. M. Leitao1, N. R. Abu-Rustum1 and C. Hogdall3
1Memorial Sloan Kettering Cancer Center, New York, NY, 2Rigshospitalet, University of Copenhagen, Copenhagen, Denmark, 3Juliane Marie Centre, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
 
5:30 PM
88
Impact of obesity on sentinel lymph node mapping in patients with newly diagnosed uterine cancer undergoing robotic surgery
A. G. Z. Eriksson, M. Montovano, A. L. Beavis, R. A. Soslow, Q. Zhou, N. R. Abu-Rustum, G. J. Gardner, R. R. Barakat, C. L. Brown, D. A. Levine, Y. Sonoda, M. M. Leitao and E. Jewell
Memorial Sloan Kettering Cancer Center, New York, NY
 
5:30 PM
89
Adherence to a standard algorithm results in high negative predictive value of sentinel lymph node assessment using indocyanine green (ICG) and isosulfane blue (ISB) dye in endometrial cancer
F. J. Backes, D. M. O'Malley, R. Salani, D. E. Cohn, L. J. Copeland and J. M. Fowler
The Ohio State University, James Cancer Hospital, Columbus, OH
 
5:30 PM
90
Pulmonary resection in the treatment of high-risk gestational trophoblastic neoplasia
M. J. Kanis and J. R. Lurain III
Northwestern University Feinberg School of Medicine, Chicago, IL
 
5:30 PM
91
A multicenter prospective assessment of surgical findings associated with suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube and peritoneal cancer
R. S. Suidan1, P. T. Ramirez2, D. A. Levine1, Y. Sonoda1, N. R. Abu-Rustum1, M. M. Leitao1, Q. Zhou1, M. K. Amangurbanova1, C. F. Levenback2 and D. S. Chi1
1Memorial Sloan Kettering Cancer Center, New York, NY, 2The University of Texas MD Anderson Cancer Center, Houston, TX
 
5:30 PM
92
Ovarian cancer patients selected for neoadjuvant chemotherapy vs. primary debulking surgery are not similar: a National Cancer Data Base study
G. S. Leiserowitz1, J. F. Lin2, A. I. Tergas3, B. A. Cliby4 and R. E. Bristow5
1UC Davis Comprehensive Cancer Center, Sacramento, CA, 2Magee-Womens Hospital of UPMC, Pittsburgh, PA, 3Columbia University College of Physicians and Surgeons, New York, NY, 4Mayo Clinic, Rochester, MN, 5University of California, Irvine, Irvine, CA
 
5:30 PM
93
Surgical complexity score and oncologic outcomes following optimal or complete cytoreductive surgery for ovarian, fallopian tube and primary peritoneal cancers
L. S. Krill1, A. Nickles Fader2, E. J. Tanner III2, M. Gerardi Fairbairn3 and R. E. Bristow4
1University of California Irvine Medical Center, Orange, CA, 2Johns Hopkins Medical Institutions, Baltimore, MD, 3Johns Hopkins Medical Institutions, Columbia, MD, 4University of California, Irvine, Irvine, CA
 
5:30 PM
94
Setting the bar: compliance with ovarian cancer quality indicators at a National Cancer Institute (NCI)-designated Comprehensive Cancer Center (CCC)
M. I. Liang1, A. C. ElNaggar2, S. Nekkanti1, D. M. O'Malley2, E. M. Hade3, L. J. Copeland2, J. M. Fowler2, R. Salani2, F. J. Backes2 and D. E. Cohn2
1The Ohio State University, Columbus, OH, 2The Ohio State University, James Cancer Hospital, Columbus, OH, 3The Ohio State University Medical Center, Columbus, OH
 
5:30 PM
95
The use of NCCN guideline therapy in the first line/adjuvant setting in patients with ovarian cancer from 6 NCCN Institutions
D. M. O'Malley1, J. Niland2, M. A. Bookman3, R. A. Burger4, M. Cristea2, J. Griggs5, G. M. Mantia-Smaldone6, L. A. Meyer7, C. C. L. Sun7, A. Wright8 and D. E. Cohn1
1The Ohio State University, James Cancer Hospital, Columbus, OH, 2City of Hope, Duarte, CA, 3University of Arizona Cancer Center, Tucson, AZ, 4University of Pennsylvania, Philadelphia, PA, 5University of Michigan Health Systems, Ann Arbor, MI, 6Fox Chase Cancer Center, Philadelphia, PA, 7The University of Texas MD Anderson Cancer Center, Houston, TX, 8Brigham and Women's Hospital/Dana Farber Cancer Institute, Boston, MA
 
5:30 PM
96
Impact of time interval from definitive surgery to initiation of adjuvant chemotherapy (ISC) on survival for advanced epithelial ovarian cancer
Y. Y. Lee1, E. J. Heo1, A. Yoon1, G. Yoon2, C. H. Choi1, T. J. Kim3, J. W. Lee3, M. K. Kim4, D. S. Bae3 and B. G. Kim3
1Samsung Medical Center, Seoul, South Korea, 2Sungkyunkwan University School of Medicine, Seoul, South Korea, 3Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, 4Sungkyunkwan University School of Medicine, Changwon-Si, South Korea
 
5:30 PM
97
A comparative analysis in management of ovarian cancer between a major tertiary cancer center and non-oncologic institutions in Medellín, Colombia
G. J. Rendón1, L. M. Echeverri1, R. Pareja1, M. Araujo2, M. A. Madariaga3, S. M. Lucchini Sr.4 and P. T. Ramirez5
1Instituto de Cancerología - Las Américas, Medellín, Colombia, 2Centro Medico Docente la Trinidad, Caracas, Venezuela, 3Hospital de San José, Bogotá, Colombia, 4Hospital Nacional de Clinicas, Cordoba, Argentina, 5The University of Texas MD Anderson Cancer Center, Houston, TX
 
5:30 PM
98
Surgical factors do not impact survival in high-grade serous ovarian carcinoma patients treated with neoadjuvant chemotherapy
J. M. Stewart1,2, A. A. Tone2, M. Q. Bernardini2, S. E. Ferguson2, J. Dodge2, S. Laframboise2, K. J. Murphy2, B. P. Rosen2 and T. May2,3
1Queen's University, Kingston, ON, Canada, 2Princess Margaret Hospital, Toronto, ON, Canada, 3Brigham and Women's Hospital, Boston, MA
 
5:30 PM
99
Preoperative thrombocytosis and leukocytosis among ovarian cancer patients is associated with postoperative death
E. L. Barber, J. F. Boggess, L. Van Le, K. H. Kim, V. L. Bae-Jump, W. R. Brewster, J. T. Soper and P. A. Gehrig
University of North Carolina at Chapel Hill, Chapel Hill, NC
 
5:30 PM
100
Distinct immune characteristics in women with deleterious germline BRCA1/2 mutations (gBRCAm)-associated high-grade serous ovarian cancer (HGSOC)
J. M. Lee, Y. Tomita, V. Chiou, S. Lee, M. Yu, N. Houston, M. J. Lee, E. C. Kohn and J. Trepel
National Cancer Institute, Bethesda, MD
 
5:30 PM
101
The acceptability and perception of the morbidity and mortality of complex surgical procedures in primary debulking of ovarian cancer: a survey of American and Canadian gynecologic oncologists
K. Pulman, A. L. Covens, G. Bouchard-Fortier, J. Hallet, P. Karanicolas and D. Vicus
University of Toronto, Toronto, ON, Canada
 
5:30 PM
102
The impact of percent reduction in CA-125 levels on prediction of the extent of interval cytoreduction and outcome in patients with advanced stage cancer of müllerian origin treated with neoadjuvant chemotherapy
H. Mahdi, K. Maurer, B. Nutter and P. G. Rose
Cleveland Clinic, Cleveland, OH
 
5:30 PM
103
Does time interval between surgery and intraperitoneal chemotherapy administration in advanced ovarian cancer carry a prognostic impact?
A. E. Garcia-Soto1, J. Java2, W. Nieves-Neira3, M. Markman4, D. K. Armstrong5 and J. M. Pearson3
1University of Miami Jackson Memorial Hospital, Miami, FL, 2Gynecologic Oncology Group Statistical and Data Center, Buffalo, NY, 3University of Miami Sylvester Comprehensive Cancer Center, Miami, FL, 4Cancer Treatment Centers of America, Meadowbrook, PA, 5Johns Hopkins Kimmel Cancer Center, Baltimore, MD
 
5:30 PM
104
Improvement in rates of cytoreduction to no residual for stages IIIB-IV ovarian, fallopian tube and primary peritoneal cancer: a change in surgical approach and individualized surgeon feedback
S. J. Lee, R. S. Suidan, M. Quincy, Y. Sonoda, D. A. Levine, M. M. Leitao, G. J. Gardner, E. Jewell, O. Zivanovic and D. S. Chi
Memorial Sloan Kettering Cancer Center, New York, NY
 
5:30 PM
105
Comparison of dose-dense and every-3-week taxane in the neoadjuvant treatment of ovarian, fallopian tube, and primary peritoneal cancer
E. M. Hinchcliff1, I. Wilkinson-Ryan2, A. A. Gockley3, K. M. Esselen1, A. R. Hagemann2, M. Auer4, Y. Tao5, D. G. Mutch2, K. C. Fuh6 and N. S. Horowitz7
1Brigham and Women's Hospital/Harvard University, Boston, MA, 2Washington University School of Medicine, St. Louis, MO, 3Massachusetts General Hospital, Boston, MA, 4The Cleveland Clinic Foundation, Cleveland, OH, 5Washington University School of Medicine, St Louis, MO, 6Stanford University, Stanford, CA, 7Harvard University, Boston, MA
 
5:30 PM
106
Impact of time of day on survival outcomes after cytoreductive surgery for advanced epithelial ovarian, tubal and peritoneal cancer
A. Yoon1, Y. Y. Lee1, C. H. Choi1, T. J. Kim2, W. Y. Kim3, J. W. Lee2, B. G. Kim2 and D. S. Bae2
1Samsung Medical Center, Seoul, South Korea, 2Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, 3Kangbuk Samsung Hospital, Seoul, South Korea
 
5:30 PM
107
Analysis of disparities in advanced ovarian cancer treatment and survival in the Medicare population using propensity score matching
R. E. Bristow1, J. Chang1, A. Ziogas1, B. Campos2, L. R. Chavez2 and H. Anton-Culver3
1University of California, Irvine, Irvine, CA, 2UC Irvine Medical Center, Orange, CA, 3University of California at Irvine, Irvine, CA
 
5:30 PM
108
Post intensive care unit syndrome in women with gynecologic cancer
C. C. Gunderson1, R. Ruskin2, A. Walter2, K. Ding1 and K. N. Moore1
1The University of Oklahoma, Oklahoma City, OK, 2The University of Oklahoma, Stephenson Cancer Center, Oklahoma City, OK
 
5:30 PM
109
Cost-effectiveness analysis of conventional laparoscopic versus robotically assisted laparoscopic adnexal surgery for benign indications performed by gynecologic oncologists
V. Broach, M. Montovano, E. Drill, M. M. Leitao, N. R. Abu-Rustum, G. J. Gardner, Y. Sonoda, O. Zivanovic, D. S. Chi, C. L. Brown, D. A. Levine, R. R. Barakat and E. Jewell
Memorial Sloan Kettering Cancer Center, New York, NY
 
5:30 PM
110
Prevalence of cervical cancer screening among women in Nepal: a nationwide population based survey
A. Ranjit1, S. Gupta2, R. Shrestha3, S. Shrestha4, A. L. Kushner1, B. C. Nwomeh5 and R. S. Groen1
1Johns Hopkins School of Medicine, Baltimore, MD, 2University of California, San Francisco, San Francisco, CA, 3Nepal Medical College Teaching Hospital, Nepal, Nepal, 4Nepal Medical College Teaching Hospital, Kathmandu, Nepal, 5Gynecologic Oncology Group Tissue Bank, Biopathology Center, Research Institute at Nationwide Children's Hospital, Columbus, OH
 
5:30 PM
111
Racial disparities in treatment of high grade endometrial cancer in the Medicare population
J. A. Rauh-Hain1, J. T. Clemmer1, D. M. Boruta II1, J. O. Schorge1, A. Buskwofie2 and M. del Carmen1
1Massachusetts General Hospital/Harvard University, Boston, MA, 2Massachusetts General Hospital, Boston, MA
 
5:30 PM
112
Racial differences in reasons for failure to receive ovarian cancer treatment
M. A. Otoo1,2, A. Beckmeyer-Borowko1, K. C. Brewer1, C. E. Peterson1,3, F. Davis4, K. Hoskins2,3 and C. E. Joslin1,2,3
1University of Illinois at Chicago School of Public Health, Chicago, IL, 2University of Illinois College of Medicine, Chicago, IL, 3University of Illinois at Chicago Cancer Center, Chicago, IL, 4University of Alberta School of Public Health, Edmonton, AB, Canada
 
5:30 PM
113
The benefits of timely palliative care referral
J. E. Stine, K. M. Doll, S. R. Pierce, S. A. Sullivan, P. A. Gehrig, L. Hanson and K. H. Kim
University of North Carolina at Chapel Hill, Chapel Hill, NC
 
5:30 PM
114
Long-term outcomes in BRCA1/2 carriers who undergo risk-reducing salpingo-oophorectomy
C. Garcia, L. Lyon, R. D. Littell and B. Powell
Kaiser Permanente Medical Group, San Francisco, CA
 
5:30 PM
115
Sexual and marital dysfunction in women with gynecologic cancer: results of a multi-institutional, cross-sectional trial
S. R. Guntupalli1, D. M. Flink2, Y. J. M. Ioffe3, J. Sheeder1, A. I. Tergas4, J. D. Wright4, S. A. Davidson1, J. Leiferman5 and K. Behbakht1
1University of Colorado Denver, Aurora, CO, 2University of Colorado Hospital, Aurora, CO, 3Washington University School of Medicine, St. Louis, MO, 4NYP/Columbia University Medical Center, New York, NY, 5University of Colorado School of Medicine, Aurora, CO
 
5:30 PM
116
Provision of primary palliative care by gynecologic oncologists
R. Ruskin1, M. Rowland1, K. N. Moore2, J. L. Walker2, L. M. Landrum2 and M. Matzo1
1The University of Oklahoma, Stephenson Cancer Center, Oklahoma City, OK, 2The University of Oklahoma, Oklahoma City, OK
 
5:30 PM
117
Postoperative morbidity and mortality following modern pelvic exenteration
E. L. Barber1, J. F. Boggess1, P. A. Gehrig1, J. T. Soper1 and N. L. Neubauer2
1University of North Carolina at Chapel Hill, Chapel Hill, NC, 2Northwestern University Feinberg School of Medicine, Chicago, IL
 
5:30 PM
118
Referral of obese endometrial cancer survivors to a bariatric specialist: weight loss attempts initiated and barriers to change
A. M. Jernigan1, K. R. Cooper2, P. G. Rose2 and C. Michener2
1Cleveland Clinic Foundation, Cleveland, OH, 2Cleveland Clinic, Cleveland, OH
 
5:30 PM
119
Measurement and validation of frailty as a predictor of outcomes in women undergoing major gynecologic surgery
E. George1, W. M. Burke2, J. Y. Hou3, A. I. Tergas2, E. Prendergast1, L. Chen3, A. Neugut3, C. Ananth3, D. Hershman3 and J. D. Wright2
1Columbia University, New York, NY, 2NYP/Columbia University Medical Center, New York, NY, 3Columbia University College of Physicians and Surgeons, New York, NY
 
5:30 PM
120
Sarcopenia as a predictor of surgical morbidity in advanced ovarian cancer patients
A. Kumar1, M. Moynagh1, B. A. Cliby2, M. McGree2, P. Young1, J. N. Bakkum-Gamez2, C. L. Langstraat2, S. C. Dowdy2, A. Jatoi2 and A. Mariani2
1Mayo Clinic College of Medicine, Rochester, MN, 2Mayo Clinic, Rochester, MN
 
5:30 PM
121
National representation of surgical outcomes and complications of pelvic exenterations for gynecologic cancers in the 21st century
N. A. Latif1, K. Williams1 and E. M. Ko2
1University of Pennsylvania, Philadelphia, PA, 2University of Pennsylvania, Penn Medicine, Philadelphia, PA
 
5:30 PM
122
Prolonged steep Trendelenburg positioning increases the risk of postoperative morbidity in patients undergoing robotic surgery for presumed gynecologic malignancy
C. L. Adams, J. Sheeder, J. Arruda, S. R. Guntupalli, S. A. Davidson and K. Behbakht
University of Colorado Denver, Aurora, CO
 
5:30 PM
123
Incidental uterine malignancy following laparoscopic supracervical hysterectomy in a national cohort
C. R. Washington1, N. A. Latif2 and E. M. Ko3
1University of Pennsylvania Medical Center, Philadelphia, PA, 2University of Pennsylvania, Philadelphia, PA, 3University of Pennsylvania, Penn Medicine, Philadelphia, PA
 
5:30 PM
124
The process of transforming pelvic exenteration to a "true" minimally invasive procedure utilizing the robotic platform
S. J. LoCoco
University of Illinois College of Medicine at Peoria, Peoria, IL
 
5:30 PM
125
National Age Standardized Rate (ASR) of ovarian cancer (OC) correlates with Human Development Index (HDI), analysis of data from 165 countries
L. M. Bean, M. A. Davis, N. R. Shah, K. M. Anderson, P. M. Workman, K. C. Kurnit, C. C. Saenz, M. T. McHale and S. C. Plaxe
UCSD Rebecca and John Moores Cancer Center, La Jolla, CA
 
5:30 PM
126
Birthplace does not modify the already elevated risk of ovarian clear cell carcinoma (CC) among Asian/Pacific Islander (API) women in the United States
T. R. K. Korenaga1, K. K. Ward2, M. T. McHale3, C. C. Saenz3 and S. C. Plaxe3
1UCSD Moores Cancer Center, San Diego, CA, 2University of Florida College of Medicine-Jacksonville, Jacksonville, FL, 3UCSD Rebecca and John Moores Cancer Center, La Jolla, CA
 
5:30 PM
127
International study of primary mucinous ovarian carcinomas managed at tertiary medical centers
J. J. Mueller1, C. Hogdall2, H. Lajer3, B. J. Mosgaard2, Y. R. Hussein1, R. A. Soslow1, D. S. Chi1, M. M. Leitao1 and N. R. Abu-Rustum1
1Memorial Sloan Kettering Cancer Center, New York, NY, 2Juliane Marie Centre, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark, 3Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
 
5:30 PM
128
Disease stabilization vs. response after bevacizumab treatment in recurrent ovarian cancer: how do we determine clinical efficacy?
K. C. Fuh1, A. A. Secord2, K. S. Bevis3, W. K. Huh3, K. Blansit4, E. Rosenfeld5, L. Hu5, R. A. Previs6, A. B. Gardner4, D. S. Kapp7 and J. K. Chan8
1Washington University School of Medicine, St Louis, MO, 2Duke University Medical Center, Durham, NC, 3University of Alabama at Birmingham, Birmingham, AL, 4Palo Alto Medical Foundation Research Institute, Palo Alto, CA, 5California Pacific Medical Center Research Institute, San Francisco, CA, 6The University of Texas MD Anderson Cancer Center, Houston, TX, 7Stanford University, Stanford, CA, 8California Pacific & Palo Alto Medical Foundation / Sutter Research Institute, San Francisco, CA
 
5:30 PM
129
Revisiting the methods to calculate carboplatin dose in women with gynecologic cancers
M. Song1, C. S. Kim2, J. Butt2, W. Shih1, M. P. Kane1 and L. Rodriguez-Rodriguez1
1Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, 2Robert Wood Johnson Medical School, New Brunswick, NJ
 
5:30 PM
130
Evaluation of the NSQIP surgical risk calculator to predict complications in gynecologic oncology patients undergoing laparotomy
C. Rivard1, E. Slagle2, R. Nahum2, R. Isaksson Vogel1 and D. G. K. Teoh1
1University of Minnesota, Minneapolis, MN, 2University of Minnesota Cancer Center, Minneapolis, MN
 
5:30 PM
131
Observed-to-expected ratio for adherence to treatment guidelines as a quality of care indicator for ovarian cancer
V. B. Galvan-Turner, J. Chang, A. Ziogas and R. E. Bristow
University of California, Irvine, Irvine, CA
 
5:30 PM
132
Therapeutic benefit of lymphadenectomy in low grade epithelial ovarian carcinoma: a national cancer database study
J. Berger, S. E. Taylor, A. L. Alexander, M. B. Courtney-Brooks, A. B. Olawaiye, J. T. Comerci, J. L. Kelley III and P. Sukumvanich
Magee-Womens Hospital of UPMC, Pittsburgh, PA
 
5:30 PM
133
Rescreening for genetic mutations using multi-gene panel testing in patients who previously underwent noninformative genetic screening
S. H. Kim, M. K. Frey, R. Yee Bassett, J. Martineau and S. V. Blank
New York University School of Medicine, New York, NY
 
5:30 PM
134
The FAK of uterine cancer: PTEN expression predicts response of uterine cancer to focal adhesion kinase inhibition
R. A. Previs1, D. Thanapprapasr1, W. Hu1, R. Rupaimoole1, J. Huang1, H. J. Dalton1, R. Ali2, G. N. Armaiz-Pena1, J. M. Hansen1, B. Zand1, R. L. Coleman1 and A. K. Sood1
1The University of Texas MD Anderson Cancer Center, Houston, TX, 2Wayne State University, Detroit, MI
 
5:30 PM
135
Molecular predictors of response to EphA2 targeted therapy in uterine cancer
A. K. Sood, J. Huang, W. Hu, R. A. Previs, H. J. Dalton, J. M. Hansen, Y. Sun, A. M. Nick, R. Broaddus and R. L. Coleman
The University of Texas MD Anderson Cancer Center, Houston, TX
 
5:30 PM
136
The landscape of somatic hypermutation in gynecologic cancer
J. S. Chapman1, M. Chang2, S. Asthana2, L. M. Chen1, N. Schultz3 and B. Taylor2,3
1UCSF Helen Diller Comprehensive Cancer Center, San Francisco, CA, 2University of California, San Francisco, San Francisco, CA, 3Memorial Sloan Kettering Cancer Center, New York, NY
 
5:30 PM
137
The metastatic role of AXL, a receptor tyrosine kinase, in a genetically engineered mouse model of metastatic, endometrioid ovarian cancer
K. C. Fuh1, E. R. Rankin2, C. W. Wu2, A. D. Diep2 and A. G. Giaccia2
1Washington University School of Medicine, St Louis, MO, 2Stanford University School of Medicine, Stanford, CA
 
5:30 PM
138
Microbial diversity in the fimbriae, fallopian tube and peritoneum in women with benign disease and advanced pelvic malignancies
B. K. Erickson, A. Subramaniam, R. Kumar, W. K. Huh and C. Morrow
University of Alabama at Birmingham, Birmingham, AL
 
5:30 PM
139
Evaluation of insulin-like growth factor 2 as a biomarker in uterine carcinosarcoma
M. Cossio1, R. C. Arend2, A. R. Van Arsdale1, B. K. Erickson2, Y. Wang1, D. W. Doo3, C. A. Leath III2, G. L. Goldberg1 and G. S. Huang1
1Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, 2University of Alabama at Birmingham, Birmingham, AL, 3University of Colorado Denver, Aurora, CO
 
5:30 PM
140
Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo
C. L. Schwab1, D. P. English1, J. D. Black1, S. Lopez2, S. Bellone1, D. M. Roque3, E. S. Ratner1, D. A. Silasi1, M. Azodi1, T. J. Rutherford1, P. E. Schwartz1 and A. Santin1
1Yale University School of Medicine, New Haven, CT, 2University Campus Bio-Medico of Rome, Rome, Italy, 3University of Maryland School of Medicine, Baltimore, MD
 
5:30 PM
141
Molecular characterization of 361 cases of uterine carcinosarcomas reveal alterations in the DNA repair and PI3K pathways as potential therapeutic targets
N. L. Jones1, J. Xiu2, S. K. Reddy2, A. I. Tergas1, W. M. Burke1, J. D. Wright1 and J. Y. Hou1
1NYP/Columbia University Medical Center, New York, NY, 2Caris Life Sciences, Irving, TX
 
5:30 PM
142
How important is the pathologic margin distance in vulvar cancer?
G. Baiocchi, H. Mantoan, L. De Brot, C. Faloppa, L. Badiglian-Filho, L. Y. Kumagai, E. Fukazawa, A. A. B. A. Costa and R. M. Rocha
A.C. Camargo Cancer Center, São Paulo, Brazil
 
5:30 PM
143
Morcellating sarcomas: failing to sample or sampling failure?
S. K. Goodrich, M. E. Buechel and J. Knight
Cleveland Clinic, Cleveland, OH
 
5:30 PM
144
Relationship between Body Mass Index (BMI) and gene expression profiles of high grade serous ovarian cancers in The Cancer Genome Atlas (TCGA) project
W. Z. Wysham1, T. H. Chen2, L. Makowski1, D. G. Mutch3, A. Berchuck4, B. Y. Karlan5, D. A. Levine6 and V. L. Bae-Jump1
1University of North Carolina at Chapel Hill, Chapel Hill, NC, 2National Cancer Institute, Bethesda, MD, 3Washington University School of Medicine, St. Louis, MO, 4Duke University Medical Center, Durham, NC, 5Cedars-Sinai Medical Center, Los Angeles, CA, 6Memorial Sloan Kettering Cancer Center, New York, NY
 
5:30 PM
145
Platinum and taxane-induced ovarian toxicity: mechanism of damage and evaluation of gonadoprotective agents
J. Berger1, P. Mital2, T. L. Beck3, M. Sukhwani2, A. Althouse2, T. C. Krivak4, J. L. Kelley III1 and K. Orwig1
1Magee-Womens Hospital of UPMC, Pittsburgh, PA, 2Magee-Womens Research Institute and Foundation, Pittsburgh, PA, 3University of Washington Medical Center, Seattle, WA, 4Western Pennsylvania Hospital, Pittsburgh, PA
 
5:30 PM
146
Advancing metformin as a metabolic therapeutic for ovarian cancer: testing in non-diabetic patient-derived xenograft avatars
K. A. Mills1, M. A. Becker2, T. Febbraro1, L. M. Litchfield1, E. Lengyel1, P. Haluska Jr.2 and I. Romero1
1University of Chicago Medicine, Chicago, IL, 2Mayo Clinic College of Medicine, Rochester, MN
 
5:30 PM
147
The HMG-CoA reductase inhibitor, simvastatin, has anti-tumorigenic effects in ovarian cancer cell lines and a genetically engineered serous ovarian cancer mouse model.
J. E. Stine, X. Han, M. Schointuch, C. Zhou, T. Gilliam, K. H. Kim, P. A. Gehrig and V. L. Bae-Jump
University of North Carolina at Chapel Hill, Chapel Hill, NC
 
5:30 PM
148
Cell-based therapy in ovarian cancer: improved adenoviral transduction strategy of human mesenchymal stem cells as tumor-homing drug factories
L. M. Kuroki1, I. Dmitriev1, J. Gibbs1, K. Tatzel1, M. A. Powell1, D. G. Mutch1, A. B. Dietz2, D. T. Curiel1, W. Hawkins1 and D. Spitzer1
1Washington University School of Medicine, St. Louis, MO, 2Mayo Clinic, Rochester, MN
 
5:30 PM
149
Progestins inhibit calcitriol-induced CYP24A1 in endometrial and ovarian cancer cells
G. C. Rodriguez1, J. Turbov1, R. Rosales1, V. Syed2, T. P. Conrads3, K. M. Darcy3, G. L. Maxwell4, C. A. Hamilton5 and L. G. Thaete1
1Northshore University Health System, Evanston, IL, 2Uniformed Services University of the Health Sciences, Bethesda, MD, 3Gynecologic Cancer Center of Excellence, Annandale, VA, 4Inova Fairfax Hospital, Falls Church, VA, 5Walter Reed National Military Medical Center, Bethesda, MD
 
5:30 PM
150
PI3K coupled to PARP inhibition demonstrates synergistic anti-tumor activity in endometrioid endometrial cancer patient derived xenografts
T. R. Hall1, C. M. DiGloria2, M. Kim2, L. Zhang2, R. Foster2, W. B. Growdon1 and B. R. Rueda2
1Massachusetts General Hospital/Harvard University, Boston, MA, 2Massachusetts General Hospital, Boston, MA
 
5:30 PM
151
Dietary isothiocyanates inhibit cancer cell growth by inducing replication stress mediated DNA damage response
R. Barnett, K. Tripathi, L. Bachaboina, U. Hussien, J. M. Scalici, R. P. Rocconi and K. Palle
University of South Alabama-Mitchell Cancer Institute, Mobile, AL
 
5:30 PM
152
Comprehensive genomic profiling of advanced stage endometrioid endometrial adenocarcinomas (EEAC) reveals differences associated with CTNNB1 mutation status and a high frequency of clinically relevant genomic alterations
J. A. Elvin1, K. Wang1, S. M. Ali1, J. Chmielecki1, P. J. Stephens1, O. Dorigo2 and J. S. Ross1,3
1Foundation Medicine, Inc., Cambridge, MA, 2Stanford Hospital and Clinics, Stanford, CA, 3Albany Medical College, Albany, NY
 
5:30 PM
153
Stathmin over-expression correlates with poor prognosis in patients with endometrial cancer
H. D. Reyes1, J. G. Bosquet2, J. M. Stephan1, M. E. McDonald1 and K. K. Leslie1
1University of Iowa Hospitals and Clinics, Iowa City, IA, 2Mayo Graduate School of Medicine, Jacksonville, FL
 
5:30 PM
154
Exon-specific p53 mutations drive different models of ovarian cancer risk
T. Odunsi-Akanji1, B. L. Seagle1, K. Eng2, K. O. Odunsi2 and S. Shahabi3
1Danbury Hospital, Danbury, CT, 2Roswell Park Cancer Institute, Buffalo, NY, 3Western Connecticut Health Network/Danbury Hospital, Danbury, CT
 
5:30 PM
155
Fuel for the fire: connecting genomics with metabolomics in ovarian cancer
R. A. Previs1, T. J. Moss1, B. Zand1, R. Rupaimoole1, H. J. Dalton1, J. M. Hansen1, G. N. Armaiz-Pena1, S. Lutgendorf2, R. L. Coleman1, P. Bhattacharya1, P. Ram1 and A. K. Sood1
1The University of Texas MD Anderson Cancer Center, Houston, TX, 2University of Iowa, Iowa City, IA
 
5:30 PM
157
Long term safety follow up, dosimetry and immunologic responses in patients enrolled on a phase I trial of intraperitoneal 212Pb labeled trastuzumab
R. Meredith1, J. Torgue2, R. D. Alvarez1, S. Shen1, D. R. Fisher3, E. Banaga2, P. Bunch1 and J. M. Straughn Jr.1
1University of Alabama at Birmingham, Birmingham, AL, 2AREVA Med, Bethesda, MD, 3Dade Moeller Health Group, Richland, WA
 
5:30 PM
158
Mesothelin-derived peptide vaccination leads to survival advantage in epithelial ovarian cancer mouse model
P. S. Binder1, S. P. Goedegebuure1, M. C. Hornick1, D. Spitzer1, M. A. Powell2, D. G. Mutch2 and W. Hawkins2
1Washington University School of Medicine, St Louis, MO, 2Washington University School of Medicine, St. Louis, MO
 
5:30 PM
159
Role of increased n-acetylaspartate levels in epithelial ovarian cancer
B. Zand, R. A. Previs, N. M. Zacharias, R. Rupaimoole, H. J. Dalton, J. M. Hansen, C. Rodriguez-Aguayo, M. Guindani, G. Lopez-Berestein, P. Bhattacharya and A. K. Sood
The University of Texas MD Anderson Cancer Center, Houston, TX
 
See more of: Featured Poster Session
<< Previous Course | Next Course >>